RecruitingNCT06379412
A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer
Sponsor
Zhujiang Hospital
Enrollment
200 participants
Start Date
Jul 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to explore the association of peptidoglycan fragments derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer is: Are peptidoglycan fragments from the gut microbiota associated with the progression of colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue obtained during surgery)
Eligibility
Inclusion Criteria2
- People who underwent total colonoscopy in gastroenteroscopy room.
- People who agree to participate in this study and are willing to sign informed consent.
Exclusion Criteria3
- Previous diagnosis of malignant tumors other than colorectal cancer.
- Received any of the following drug treatments within 1 month before sample collection: ① Drugs used for the treatment of colorectal diseases; ② Antibiotics; ③probiotics; ④ Laxatives.
- Patients with a family history of colorectal cancer.
Interventions
OTHERobservational study, no intervention
observational study, no intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06379412
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT070717141 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations